Laevoroc Oncology Launches With Three-Pronged Strategy
Exclusive Interview With CEO Thomas Mehrling
Following early investor conversations, Laevoroc Oncology has split its leading products into three independent subsidiaries to off-set risk and provide greater choice to future partners. While there is no underlying platform technology, CEO Thomas Mehrling believes the subsidiaries all include potential “game-changing medicines.”
You may also be interested in...
Drug manufacturers still have a variety of ways to limit the impact of the Biden administration’s historic decision. Whether the huge political loss for industry translates into more than just headline-risk or faster global COVID vaccination remains to be seen. It's also not clear whether it’s an ominous sign for other industry battles in the US, including the drug pricing debate.
With $250m in series A funding, Cambridge, MA-based Centessa is looking to upend traditional biopharma R&D models. The new company was created through the merger of 10 private biotechs, which will sit under the Centessa umbrella as subsidiaries.
In this installment of our VC Playbook series, In Vivo sits down with Isabelle de Cremoux, CEO of Seventure. The company has been a pioneer investor in the microbiome space, which Cremoux believes has now reached a turning point.